Top Markets
Coin of the day
Regulus Therapeutics Inc. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

RGLS
Rank in Stocks #17592
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Share Price
$8.16
Last synced: 2025-06-26
Market Cap
$234.57M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Regulus Therapeutics Inc. (RGLS)

Category

Stock price history for Regulus Therapeutics Inc. (RGLS)
Highest end of day price: $8.13 on 2025-06-01

Lowest end of day price: $542.40 on 2012-10-01
Stock price history of Regulus Therapeutics Inc. from 2012 to 2026
Annual Stock Price Performance
Year Performance
2025 412.85%
2024 18.41%
2023 -5.90%
2022 -59.58%
2021 -68.07%
2020 52.53%
2019 -42.38%
2018 -88.97%
2017 -61.61%
2016 -73.01%
2015 -43.68%
2014 142.24%
2013 35.08%
2012 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$556.43 38.76%
US
$1.05K 48.60%
NL
$152.82 531.75%
US
$122.21 -10.03%
AU
$757.71 8.20%
CH